Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joseph Haas

Joseph Haas is a senior writer for Informa’s pharmaceutical news publications, with more than eight years covering the biopharmaceutical industry. He previously worked in public affairs for a real estate trade association and wrote about housing and real estate before moving into healthcare. Most recently, he was managing editor of a newsletter publisher, leading its coverage of the implementation of the Medicare Part D prescription drug benefit. Joe’s areas of expertise include business development, mergers and acquisitions, infectious diseases and liver diseases, including hepatitis C, hepatitis B and non-alcoholic steatohepatitis (NASH). He edits the popular Deal Watch column and enjoys profiling start-up companies. 
Advertisement
Set Alert for Articles By Joseph Haas

Latest From Joseph Haas

Pharma Q3 Results Preview: Biogen, Gilead, Celgene

Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon. 

Sales & Earnings Business Strategies

Deal Watch, Licensing & Alliances: Amgen Places $66m Bet On Genetic Sequencing

Already partnered with Oxford Nanopore through its acquisition of deCODE Genetics, Amgen invests in the UK biotech to enhance its genomic capabilities. Aclaris licenses dermatology product Rhofade from Allergan. Other recent licensing and alliance deals... 

Deals Business Strategies

Deal Watch, M&A: Warp Drive And Its Partnerships Acquired By Revolution

Once expected to be absorbed by Sanofi, US biotech Warp Drive Bio now will become part of California’s Revolution Medicines in a stock transaction. Sosei elects against its option to acquire MiNA Therapeutics; MeiraGTX follows its June IPO with takeout of Vector Neurosciences. Other recent mergers and acquisitions... 

M & A Deals

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a prolific platform – and AbbVie is paying $100m up front for preclinical oral integrin inhibitors for fibrosis indications, potentially including NASH.

Deals Liver & Hepatic

Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership

Amicus announced its ambitions in gene therapy last year, recently purchased Celenex and 10 pipeline candidates, and now partners with Penn on gene therapies. Celltrion is collaborating with Emory in atherosclerosis therapies.

Deals Intellectual Property

J&J Pharma Growth Led By Oncology; Firm Tries To Assuage Zytiga Concerns

The pharmaceutical business continues to withstand the arrival of more Remicade biosimilars and the firm maintains it will have solid growth even with generic competition to its Zytiga.

Sales & Earnings Business Strategies
See All
Advertisement
UsernamePublicRestriction

Register